Zydus Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Zydus Pharmaceuticals's estimated annual revenue is currently $56.3M per year.
- Zydus Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- Zydus Pharmaceuticals has 280 Employees.
- Zydus Pharmaceuticals grew their employee count by 22% last year.
Zydus Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | Associate VP, Marketing and Product Management | Reveal Email/Phone |
2 | Associate VP, National Accounts | Reveal Email/Phone |
3 | SVP - Injectables Business | Reveal Email/Phone |
4 | Head IT | Reveal Email/Phone |
5 | AVP Supply Chain & Logistics | Reveal Email/Phone |
6 | Director, National Accounts | Reveal Email/Phone |
7 | Senior Director, Human Resources & Administration | Reveal Email/Phone |
8 | General Counsel & Compliance Officer | Reveal Email/Phone |
9 | Director National Account at Zydus Pharmaceuticals USA, Inc. | Reveal Email/Phone |
10 | Sr. Director, Head U.S. Animal Health | Reveal Email/Phone |
Zydus Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Zydus Pharmaceuticals?
Company Overview Zydus Pharmaceuticals (USA) Inc. is a globally integrated generic pharmaceutical company with a focus on providing high service, quality and affordable products. Our leadership, which has over 50 years of US generic market experience, understands our customer's business which allows Zydus Pharmaceuticals the ability to provide unique models to help drive their success. Though a relatively new company in the US market, our parent Zydus Cadila has a large presence in the global markets, including relationships with many top tier international pharmaceutical companies. Based on a manufacturing and development history that spans over 55 years, our experience and knowledge affords us the ability to have one of the largest and most aggressive DMF and finished product pipelines in the industry. Over the next three years we will be filing on average two additional products and DMFs per month. Through 2007 we will exceed that goal by filing over 70 products and 60 DMFs. We are capable to support that growth with the largest, state-of-the-art, cGMP, FDA approved formulation plant in India boasting a capacity near 12 billion units. We also have two FDA approved API plants with capacities exceeding 280 metric tons. Our sustained release technology and ability to manufacture tablet, capsule, soft gel, sterile liquids, injectables, inhalers, topicals and trans-dermal patch dosage forms allows us to target even the most difficult of products. Once manufactured, our packaging area is equipped to handle special customer requests such as bulk, unit-of-use, blister, and child-resistant consumer product packaging. Zydus Pharmaceuticals (USA) Inc. is located in Pennington, New Jersey. To learn more, please contact us through this website or call (609)730-1900.
keywords:N/AN/A
Total Funding
280
Number of Employees
$56.3M
Revenue (est)
22%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Zydus Pharmaceuticals News
Mylan; Zydus Pharmaceuticals; Amneal Pharmaceuticals; Teva; Sinepharm; Beijing Jialin Pharmaceutical. The market is fragmented into the...
Zydus Pharmaceuticals; Teva; Hikma Pharmaceuticals; Natco Pharma; Fresenius Kabi; Accord Healthcare; Mylan; Cipla; Apotex; HISUN; Chongqing...
Nomura said companies whose earnings could disappoint the least were Torrent Pharma, Gland Pharma, Zydus Lifesciences and Dr Lal Pathlabs.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $70.1M | 374 | 1% | N/A |
#2 | $15960M | 421 | N/A | N/A |
#3 | $104M | 462 | N/A | N/A |
#4 | $111.6M | 496 | 2% | N/A |